ZNF593 Antibody

What is ZNF593 and what are its primary functions in cellular biology?

ZNF593 is a zinc finger protein with a molecular weight of approximately 15 kDa (134 amino acids) that functions as a transcriptional regulator. It has several key cellular roles:

• Promotes pre-60S ribosomal particles maturation by facilitating nuclear export of the 60S ribosome

• Negatively modulates the DNA binding activity of Oct-2 and its transcriptional regulatory activity

• Participates in DNA damage repair pathways, particularly homologous recombination

• Regulates cell cycle progression through modulation of cyclin genes (CCND1, CCNE1, and CCNA2)

• Influences the tumor immune environment

Research has recently identified ZNF593 as an understudied oncogene in breast cancer, where it is significantly upregulated in cancer tissues compared to adjacent normal tissues .

What is the expected molecular weight when detecting ZNF593 in Western blots?

The predicted molecular weight of ZNF593 is 15 kDa based on its 134 amino acid composition, which aligns with observations in Western blot experiments . Researchers should expect to detect:

This consistency between predicted and observed molecular weights provides reliable validation for antibody specificity in Western blot applications .

What is the tissue expression pattern and subcellular localization of ZNF593?

ZNF593 expression has been documented in:

• Mouse spleen tissue (positive Western blot detection)

• PC-3 cells (human prostate cancer cell line)

• Breast cancer tissues (significantly upregulated compared to adjacent normal tissue)

Expression analysis reveals that ZNF593 is particularly elevated in triple-negative breast cancer (TNBC) compared to luminal and HER2-positive subtypes (p < 0.01) . Subcellular localization studies indicate that ZNF593 is primarily found in the nucleus, consistent with its role in transcriptional regulation and DNA damage repair processes .

How should researchers select an appropriate ZNF593 antibody for specific experimental applications?

When selecting a ZNF593 antibody, consider these key factors:

• Application compatibility:

  • For Western blot: Multiple validated antibodies are available with recommended dilutions of 1:500-1:1000

  • For immunofluorescence: Antibodies tested in HeLa cells at 10μg/ml concentration have shown positive results

  • For ELISA: Specific antibodies validated for this application

• Species reactivity requirements:

  • Human-specific antibodies: Important for clinical samples

  • Human/mouse cross-reactive antibodies: Essential for comparative or translational studies

  • Verify reactivity with your experimental model organism

• Host species and clonality:

  • Mouse polyclonal antibodies: Available for human samples

  • Rabbit polyclonal antibodies: Available for both human and mouse samples

• Validation evidence:

  • Published applications: Some antibodies have been validated in knockout/knockdown studies

  • Western blot detection: Validated in transfected vs. non-transfected cells

Select antibodies with demonstrated specificity in your experimental system and application of interest.

What methods effectively validate ZNF593 antibody specificity?

A comprehensive validation strategy should include:

• Genetic validation approaches:

  • Knockdown/knockout controls: The most stringent validation method; several ZNF593 antibodies have been validated in KD/KO systems

  • Overexpression systems: Testing in ZNF593-transfected 293T cells versus non-transfected controls

• Technical validation parameters:

  • Band size verification: Confirm detection at the expected 15 kDa molecular weight

  • Signal specificity: Evaluate signal-to-noise ratio across different sample types

  • Cross-reactivity assessment: Test against related zinc finger proteins

• Application-specific validation:

  • For Western blot: Compare detection in positive control tissues (mouse spleen) versus negative controls

  • For immunofluorescence: Verify expected nuclear localization pattern

  • For immunoprecipitation: Confirm pull-down efficiency with Western blot

Proper validation is crucial for ensuring reliable and reproducible research findings when studying ZNF593.

What are the optimal conditions for detecting ZNF593 by Western blot?

Based on validated protocols, these conditions yield optimal results for ZNF593 Western blot detection:

• Sample preparation:

  • Recommended positive controls: Mouse spleen tissue or PC-3 cells

  • Protein loading: 15-20 μg of total protein per lane

  • Denaturing conditions: Standard SDS-PAGE with reducing agent

• Antibody parameters:

  • Primary antibody dilution: 1:500-1:1000 (19426-1-AP or similar)

  • Incubation conditions: Overnight at 4°C or 2 hours at room temperature

  • Secondary antibody: Anti-rabbit or anti-mouse HRP conjugate (1:2500)

• Detection specifics:

  • Expected band size: 15 kDa

  • Detection method: Enhanced chemiluminescence (ECL)

  • Exposure times: Start with 30 seconds, adjust as needed

• Troubleshooting tips:

  • For weak signals: Increase protein loading or decrease antibody dilution

  • For high background: Increase blocking time or washing steps

  • For non-specific bands: Optimize antibody concentration or try alternative blocking reagents

Following these guidelines should yield a specific band at 15 kDa with minimal background interference.

How can ZNF593 antibodies be utilized to investigate DNA damage repair mechanisms?

ZNF593's involvement in DNA damage repair can be investigated through these methodological approaches:

• DNA damage response visualization:

  • Co-immunofluorescence with ZNF593 and γH2AX antibodies to assess localization to DNA damage sites

  • Time-course analysis of ZNF593 recruitment following DNA damage induction

• Functional assessment:

  • Western blot evaluation of γH2AX levels in ZNF593 knockdown models (increased γH2AX indicates compromised repair)

  • RAD50 expression analysis in ZNF593-depleted cells (research shows decreased RAD50 with ZNF593 knockdown)

  • Homologous recombination repair assays using reporter constructs

• Chemosensitivity studies:

  • Cell viability assays with DNA-damaging agents:

    • Cisplatin and carboplatin have demonstrated enhanced efficacy in ZNF593-depleted breast cancer cells

    • Dose-response curves should be generated to quantify sensitivity differences

• Mechanistic investigations:

  • Co-immunoprecipitation to identify interactions with DNA repair proteins

  • ChIP assays to assess ZNF593 binding to DNA damage-responsive gene promoters

  • Analysis of HR pathway component expression and activation

This multi-faceted approach provides comprehensive insights into ZNF593's role in maintaining genomic stability and drug resistance mechanisms.

What methodologies can reveal ZNF593's influence on cell cycle progression?

To investigate ZNF593's role in cell cycle regulation, employ these experimental approaches:

• Cell cycle phase analysis:

  • Flow cytometry with propidium iodide staining in control versus ZNF593-depleted cells

  • EdU incorporation assays to quantify S-phase entry

  • Time-lapse microscopy to measure mitotic duration

• Molecular pathway assessment:

  • Western blot analysis of cyclins modulated by ZNF593:

    • CCND1 (Cyclin D1): G1/S transition regulator

    • CCNE1 (Cyclin E1): G1/S transition regulator

    • CCNA2 (Cyclin A2): S phase progression regulator

  • RT-qPCR to determine transcriptional effects on these cyclin genes

• Proliferation and survival assays:

  • Colony formation assays in ZNF593-modulated cells

  • MTS/MTT viability assays following ZNF593 knockdown

  • 3D spheroid growth assays for more physiologically relevant models

• Mechanistic investigations:

  • ChIP analysis to identify direct ZNF593 binding to cell cycle gene promoters

  • Cell synchronization experiments to pinpoint when ZNF593 exerts its regulatory effects

  • Rescue experiments restoring individual cyclins in ZNF593-depleted cells

These techniques collectively provide a comprehensive understanding of how ZNF593 influences cancer cell proliferation through cell cycle regulation.

How is ZNF593 expression associated with breast cancer subtypes and prognosis?

ZNF593 shows distinctive expression patterns across breast cancer subtypes with significant clinical implications:

• Expression differences by subtype:

  • Triple-negative breast cancer (TNBC): Highest ZNF593 expression

  • Luminal subtypes: Significantly lower expression compared to TNBC (p < 0.01)

  • HER2-positive subtype: Significantly lower expression compared to TNBC (p < 0.01)

• Clinical correlations:

  • Elevated ZNF593 expression is associated with poor prognosis

  • Higher expression correlates with advanced clinicopathological features

  • Premenopausal patients show significantly higher ZNF593 expression than perimenopausal patients

• Comparative expression analyses:

  • Significant upregulation in breast cancer tissues compared to adjacent normal tissues

  • Consistent elevation observed at both mRNA (qPCR) and protein (IHC, Western blot) levels

  • IHC images from the Human Protein Atlas database confirm higher expression in cancer tissues

These findings suggest ZNF593 may serve as both a prognostic marker and potential therapeutic target, particularly in aggressive TNBC.

What research approaches can elucidate ZNF593's contribution to breast cancer development?

Investigating ZNF593's role in breast cancer requires multiple complementary approaches:

• Functional genomics analyses:

  • Gene co-expression network analysis revealed ZNF593 associates with genes involved in:

    • DNA damage response

    • ATP biosynthetic processes

    • Subtelomeric heterochromatin formation

    • Cell cycle regulation, particularly mitotic processes

  • Protein-protein interaction (PPI) analysis identified 20 interacting partners including:

    • PRDX4 and LTA4H (immune system-related)

    • NSD2 (DNA damage repair-related)

    • cGAS (both DNA repair and immune system-related)

    • SSB and DNPH1 (nucleic acid binding and metabolism)

    • USO1 (mitosis process)

• Cellular phenotype investigations:

  • Proliferation assays demonstrate ZNF593 enhances breast cancer cell proliferation

  • Migration assays show ZNF593 promotes breast cancer cell migration capabilities

  • Drug sensitivity testing reveals ZNF593 knockdown enhances sensitivity to cisplatin and carboplatin

• Mechanistic studies:

  • DNA damage repair evaluation through γH2AX and RAD50 expression analysis

  • Cell cycle regulation through cyclin expression assessment

  • Immune environment modulation through ESTIMATE score and ssGSEA analyses

These methodologies provide comprehensive insights into ZNF593's multifaceted contribution to breast cancer biology.

How does ZNF593 influence the tumor immune microenvironment?

ZNF593 has been found to modulate the tumor immune microenvironment through several mechanisms:

These findings have important implications for potential combination therapies targeting both ZNF593 and immune checkpoints.

What controls are essential when interpreting ZNF593 expression data?

To ensure valid interpretation of ZNF593 expression studies, implement these critical controls:

• Positive controls:

  • Validated cellular models: Mouse spleen tissue and PC-3 cells show reliable ZNF593 expression

  • Overexpression systems: ZNF593-transfected 293T cells provide strong positive signal

  • TNBC samples: Highest naturally occurring expression among breast cancer subtypes

• Negative controls:

  • ZNF593 knockdown/knockout samples: Essential for validating antibody specificity

  • Non-transfected cell lysates: Appropriate comparison for overexpression models

  • Adjacent normal breast tissue: Significantly lower expression compared to tumor tissue

• Technical controls:

  • Loading controls: Use established housekeeping proteins appropriate for your experimental system

  • Antibody validation: Include primary antibody omission controls

  • Multiple detection methods: Confirm findings using both protein (Western blot/IHC) and mRNA (qPCR) analyses

• Experimental design considerations:

  • Include multiple breast cancer subtypes when studying differential expression

  • Consider patient characteristics (e.g., menopausal status) that may influence expression

  • Account for tumor heterogeneity through multiple sampling when possible

Proper implementation of these controls ensures reliable data interpretation and reproducibility.

How can discrepancies between mRNA and protein expression of ZNF593 be reconciled?

When mRNA and protein expression patterns for ZNF593 don't align, consider these explanations and methodological approaches:

• Post-transcriptional regulation mechanisms:

  • MicroRNA targeting: Assess potential miRNA binding sites in ZNF593 mRNA

  • RNA stability factors: Examine RNA binding protein interactions

  • Translation efficiency: Polysome profiling to assess translation rates

• Post-translational modification influences:

  • Protein stability: Cycloheximide chase assays to determine ZNF593 half-life

  • Degradation pathways: Proteasome inhibition experiments to assess turnover rates

  • Modification-specific detection: Phosphorylation or ubiquitination-specific antibodies

• Methodological considerations:

  • Sample preparation differences: Protein extraction methods may not capture all cellular compartments

  • Detection sensitivity variations: qPCR may detect low abundance transcripts missed by protein methods

  • Temporal dynamics: Time-course experiments to capture expression changes over time

• Experimental validation approaches:

  • Multiple antibodies: Use antibodies targeting different epitopes of ZNF593

  • Fractionation studies: Assess nuclear versus cytoplasmic distribution

  • Correlative analyses: Large-scale studies examining mRNA-protein correlation across multiple conditions

These approaches provide a systematic framework for investigating and explaining observed discrepancies.

What are the current limitations in ZNF593 research and future directions?

Current research on ZNF593 faces several limitations that present opportunities for future investigation:

• Methodological limitations:

  • Overexpression validation: Current studies focus primarily on knockdown effects without complementary overexpression experiments

  • Clinical sample size: Limited clinical follow-up data (66 samples in recent studies) necessitates larger cohorts for prognostic validation

  • Mechanistic depth: While associations with DNA repair, cell cycle, and immune function are established, detailed molecular mechanisms remain to be elucidated

• Research opportunities:

  • Structure-function analysis: Identifying critical domains of ZNF593 responsible for specific cellular functions

  • Post-translational modifications: Characterizing how modifications regulate ZNF593 activity

  • Transcriptional targets: Comprehensive identification of genes directly regulated by ZNF593

  • Therapeutic targeting: Development of small molecules or peptides to modulate ZNF593 function

• Technological approaches needed:

  • Proteomics analyses to identify the complete ZNF593 interactome

  • CRISPR screening to identify synthetic lethal interactions with ZNF593

  • Patient-derived organoids to validate findings in more physiologically relevant models

  • In vivo models to assess ZNF593's role in tumor progression and metastasis

• Translational potential:

  • Development of ZNF593 as a biomarker for therapy response, particularly for DNA-damaging agents

  • Exploration of ZNF593 inhibition as a sensitization strategy for chemotherapy

  • Investigation of combination approaches targeting both ZNF593 and immune checkpoints

Addressing these limitations will advance our understanding of ZNF593's role in cancer biology and therapeutic applications.